International Society of Urological Pathology Consensus on Cancer Precursor Lesions. Working Group 1

Author:

Iczkowski Kenneth A.1,De Marzo Angelo M.2,Agarwal Neeraj3,Berman David M.4,Cimadamore Alessia5,Fine Samson W.6,Greenland Nancy7,Khani Francesca8,Loda Massimo8,Lotan Tamara L.9,Varma Murali10,Chinnaiyan Arul11,Giannarini Gianluca12,Huang Jiaoti13,Montironi Rodolfo1415,Netto George J.16,Osunkoya Adeboye O.17,Ratliff Timothy18,Kristiansen Glen19,Cheng Liang204,van Leenders Geert J.L.H.21,

Affiliation:

1. Department of Pathology and Laboratory Medicine, University of California—Davis Health, Sacramento

2. Departments of Pathology, Urology and Oncology, The Sidney Kimmel Comprehensive Cancer Center and The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD

3. Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

4. Surgery (Urology), Warren Alpert Medical School, the Legorreta Cancer Center at Brown University, and Brown University Health, Brown University, Providence, RI

5. Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada

6. Department of Pathology and Laboratory Medicine, Memorial Sloan-Kettering Cancer Center

7. Department of Pathology, University of California—San Francisco, San Francisco, CA

8. Pathology and Laboratory Medicine at Weill Cornell Medicine, New York, NY

9. Department of Pathology, Johns Hopkins University, Baltimore, MD

10. Cellular Pathology, University Hospital of Wales, Cardiff, UK

11. Department of Pathology, University of Michigan, Ann Arbor, MI

12. Department of Urology, Santa Maria della Misericordia University Hospital, Udine, Italy

13. Department of Pathology, Duke University, Durham, NC

14. Institute of Pathological Anatomy, Università Politecnica delle Marche

15. Molecular Medicine and Cell Therapy Foundation, Polytechnic University of the Marche Region, Ancona

16. Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

17. Departments of Pathology and Urology, Emory University School of Medicine, Atlanta, GA

18. Purdue University College of Veterinary Medicine, West Lafayette, IN

19. Institute of Pathology, Bonn, Germany

20. Pathology and Laboratory Medicine

21. Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands

Abstract

Working Group 1 at ISUP’s Cancer Precursors meeting (September 2024) evaluated 5 putative precursors of invasive prostate cancer: high-grade prostatic intraepithelial neoplasia (HGPIN), intraductal carcinoma (IDC), atypical intraductal proliferation (AIP), atypical adenomatous hyperplasia (AAH)/adenosis, and proliferative inflammatory atrophy (PIA). Objectives were to compile recent evidence, interrogate current practices, and vote on recommendations, with 67% approval defined as consensus. Consensus was reached against the reporting of the low-grade form of PIN. HGPIN need not be reported when concomitant cancer or atypical small acinar proliferation suspicious for cancer exists adjacent to it, for biopsy or prostatectomy specimens. Finally, while the clinical significance of unifocal HGPIN in biopsies remains uncertain, there is stronger evidence for multifocal isolated HGPIN as a predictor of subsequent cancer detection. By consensus, multifocal HGPIN should continue being reported. Slight refinement was achieved regarding IDC criteria. The consensus opinion was that a dense cribriform to solid proliferation need not demonstrate marked nuclear atypia/ pleomorphism to qualify as IDC. The inverse scenario of marked atypia without dense cribriform/solid proliferation fell just short (65%) of consensus for IDC. Redesignating cribriform HGPIN as AIP achieved consensus. AIP found alone or with grade group 1 cancer warrants an explanatory comment. However, agreement was not attained to report AIP in the presence of invasive cancer, in either needle biopsy or prostatectomy. Finally, the optional reporting of PIA or AAH/adenosis in biopsies as pertinent negatives both fell short of consensus. This guidance should help pathologists standardize reporting, staying focused on the clinically actionable aspects of these lesions.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference106 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3